<div id="readability-page-1"><p>H.C. Wainwright analyst Emily Bodnar has reiterated their neutral  stance on <span>GERN</span> stock, giving a Hold rating on November 28.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Emily Bodnar’s rating is based on Geron’s recent restructuring efforts aimed at achieving profitability by the second half of 2026. The company has announced a significant reduction in its workforce, which is expected to substantially decrease operating expenses by 2026. Despite these efforts, Geron’s current revenue from Rytelo has not met expectations, with recent figures showing stagnation. <br/> The restructuring plan includes a focus on expanding US commercial sales and pursuing international opportunities, particularly in Europe. Additionally, the company is awaiting results from the Phase 3 IMpactMF trial. While these strategic moves are promising, the current financial performance and market conditions have led to a Hold rating, as the company is still navigating its path to profitability.</p> <p>In another report released on November 28, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.</p> </div>

GERN

<p>H.C. Wainwright analyst Emily Bodnar maintains a Hold rating on Geron stock due to its restructuring efforts aimed at profitability by 2026, despite stagnant revenue from Rytelo. The company plans to cut workforce costs and expand US and European sales. A Phase 3 trial result is awaited. TR | OpenAI also reiterates a Hold rating with a $1.00 price target.</p>

Geron’s Restructuring Efforts and Strategic Focus Lead to Hold Rating Amidst Revenue Stagnation